Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Circulation: Heart Failure

• Publication date

  2016-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCHEARTFAILURE.115.002638PMID 27413035PMCID PMC4948953
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Approach to diabetes management in patients with CVD.

  2016influential reference
• Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.

  2015cited by this paper
• Late-Breaking Clinical Trial Abstracts.

  2015cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2015cited by this paper
• Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry

  2015cited by this paper
• Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy.

  2015cited by this paper
• Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

  2015cited by this paper
• Glycemia Lowering and Risk for Heart Failure: Recent Evidence from Studies of Dipeptidyl Peptidase Inhibition

  2015cited by this paper
• Concomitant diabetes mellitus and heart failure.

  2015cited by this paper
• Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure.

  2015cited by this paper
• Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial.

  2015influential reference
• Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

  2014cited by this paper
• Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

  2014cited by this paper
• Diabetes medications and heart failure: recognizing the risk.

  2014influential reference
• Metformin in patients with type 2 diabetes and kidney disease: a systematic review.

  2014influential reference
• Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure: Systematic Review of Observational Studies Involving 34 000 Patients

  2013influential reference
• Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  2013cited by this paper
• Action to Control Cardiovascular Risk in Diabetes

  2013cited by this paper
• Basal insulin and cardiovascular and other outcomes in dysglycemia.

  2012cited by this paper
• Comorbidity, hypoglycaemia and appropriate selection of antidiabetic pharmacotherapy in diabetic patients with heart failure in clinical practice in Germany

  2012cited by this paper
• Risk of Death and Cardiovascular Outcomes with Thiazolidinediones: A Study with the General Practice Research Database and Secondary Care Data

  2011cited by this paper
• Influence of renal function on the use of guideline-recommended therapies for patients with heart failure.

  2010cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.

  2008cited by this paper
• Quality of care and outcomes among patients with heart failure and chronic kidney disease: A Get With the Guidelines -- Heart Failure Program study.

  2008cited by this paper
• Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.

  2007cited by this paper
• High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database.

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Secondary Prevention of Macro Vascular Events in Patients With Type II Diabetes in the PROactive Study (PROspective Pioglitazone Clinical Trial and Macro Vascular Events): A Randomised Controlled Trial

  2006cited by this paper
• [DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease].

  2006cited by this paper
• Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

  2006cited by this paper
• Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).

  2005cited by this paper
• Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes

  2004cited by this paper
• The American Heart Association Get With The Guidelines program.

  2004cited by this paper
• Using "get with the guidelines" to improve cardiovascular secondary prevention.

  2003cited by this paper
• Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure.

  2002cited by this paper
• Late-Breaking Clinical Trial Abstracts

  2002cited by this paper

• Missed opportunities to manage complex comorbidity of heart failure, type 2 diabetes mellitus and chronic kidney disease: a retrospective cohort study

  2025cites this paper
• Clinical Periodontal Evaluation and Assessment of Dipeptidyl-Peptidase-4 and Galectin-3 in Gingival Crevicular Fluid of Periodontitis Patients with Heart Failure and Diabetes

  2025influential citation
• Rhythm and rate control strategies in patients with long-standing persistent atrial fibrillation treated with cardiac resynchronization: the results of the randomized Pilot-CRAfT study.

  2024cites this paper
• Medical Therapy Before, During, and After Hospitalization in Medicare Beneficiaries with Heart Failure and Diabetes: The Get With The Guidelines - Heart Failure Registry.

  2023cites this paper
• METFORMIN IS LINKED TO REDUCED MORTALITY IN TYPE 2 DIABETES WITH COMORBID CKD AND CHF: A SYSTEMATIC REVIEW

  2023influential citation
• A Novel Chronic Kidney Disease Phenotyping Algorithm Using Combined Electronic Health Record and Claims Data

  2023cites this paper
• Pathophysiology and Management of Chronic Heart Failure

  2022cites this paper
• The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial

  2021influential citation
• Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR‐TIMI 53 cardiovascular outcomes trials

  2021cites this paper
• Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020

  2021cites this paper
• Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial

  2021cites this paper
• Diabetes and treatment of chronic heart failure in a large real‐world heart failure population

  2021cites this paper
• National Trends in Diabetes Medication Use in the United States: 2008 to 2015

  2020cites this paper
• Prevalence and coprevalence of chronic comorbid conditions in patients with type 2 diabetes in Catalonia: a population-based cross-sectional study

  2019cites this paper
• Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America.

  2019cites this paper
• Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America.

  2019cites this paper
• Metformin Use and Clinical Outcomes among Patients with Diabetes with or without Heart Failure or Kidney Dysfunction: Observations from the SAVOR-TIMI 53 Trial.

  2019cites this paper
• Association Between Type 2 Diabetes and All-Cause Hospitalization and Mortality in the UK General Heart Failure Population: Stratification by Diabetic Glycemic Control and Medication Intensification.

  2018cites this paper
• Patterns of glucose‐lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR)

  2018cites this paper
• Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison

  2018cites this paper
• A Statistical Analysis of the Treatment of Type 2 Diabetes in the Presence of Chronic Kidney Disease in Patients Hospitalized for Heart Failure

  2018cites this paper
• Effect of multimorbidity on survival of patients diagnosed with heart failure: a retrospective cohort study in Singapore

  2018cites this paper
• Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials

  2017cites this paper
• Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease: A Clinical Conundrum.

  2016cites this paper